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CASE REPORT
Low sensitivity of conventional fungal agars 
in fungemia by Rhodotorula mucilaginosa: 
description of two cases
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Sara María Quevedo1 and María José Buitrago3* 
Abstract 
Background: Although most bloodstream yeast infections are caused by Candida spp., infections by rare or less 
common species have increased in recent years. Diagnosis of infections caused by these species is difficult due to the 
lack of specific symptoms and adequate diagnostic tools.
Cases presentation: We describe two cases of fungemia by Rhodotorula mucilaginosa within a few months of each 
other, in a secondary Spanish hospital. In both cases, diagnosis was challenging. Blood subcultures in conventional 
fungal media were persistently negatives and the use of non‑conventional fungal media was essential for isolating 
the yeasts and achieving a correct diagnosis. 1–3 beta‑d‑glucan detection and a panfungal PCR assay were helpful 
techniques to confirm the diagnosis
Conclusion: It is highly important to establish an early diagnosis for fungemia. The process is challenging because 
often non‑specific symptoms are presents. When yeasts grow in blood cultures other genera than Candida spp. could 
be the cause of infection. Patient risk factors should be assessed to incorporate alternative culture media and the 
available rapid diagnostic test, in order to provide an early recognition of the pathogen.
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Background
Diagnosis of invasive fungal infections (IFI) is challenging 
due to a lack of specific symptoms and adequate diagnos-
tic tools. While fungemia being the easiest one to identify 
via blood cultures, the sensitivity varies according to the 
technique used and the pathogen involved. Fungi are iso-
lated in 10% of cases, 3.3% of them in mixed forms [1]. 
Although most bloodstream yeast infections are caused 
by Candida spp., recent years have seen an increase of 
infections by rare or less common yeast species such as 
Trichosporon, Cryptococcus, Saccharomyces, Malasse-
zia and Rhodotorula spp [2]. In the described cases of 
fungemia by Rhodotorula spp., the main species involved 
is Rhodotorula mucilaginosa (also known as Rhodotorula 
rubra [3–6]). The mortality rate of fungemia by Rhodoto-
rula spp. was reported as being 14.4% in a retrospective 
review [6]. In this report, fungemia not associated with 
central venous catheter (CVC) had a higher mortality 
rate than endocarditis and CVC fungemia (20% vs 14.2% 
vs 13.5%). This increased mortality is due to several rea-
sons: (i) the population affected [7] (immunosuppressed 
patients and patients with risk factors such as CVC, peri-
toneal dialysis or parenteral nutrition), (ii) diagnostic dif-
ficulty and (iii) resistance to echinocandins [4, 5, 8–10]. 
To highlight the difficulty involved in achieving a correct 
diagnosis, we present two cases of fungemia due to R. 
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mucilaginosa that occurred in a secondary hospital (350 
beds) within a 3-month period where conventional fun-
gal agars were useless and only potato dextrose agar was 
helpful to isolate the fungus.
Cases presentation
Case 1
A severely malnourished 49-year-old male with Crohn’s 
disease, treated with  Imurel® since 1999 and  Infliximab® 
since 2015, and a double-J catheter carrier due to 
hydronephrosis grade II/IV, received care at the emer-
gency room of the Hospital Universitario Severo Ochoa 
(Leganes, Madrid) on November 20th, 2017 (day 0) 
due to severe hypomagnesemia (1  mg/dl). As a low-
grade fever of 37.6  °C was found, urine and blood were 
extracted for cultures and he was discharged after bio-
chemical correction. On day + 5, upon visualizing yeasts 
in two blood cultures (Versa TREK™ Automated Culture 
System, Thermo Scientific), the patient was called back to 
the hospital where he recorded a temperature of 37.4 °C 
without any other symptoms. Empirical treatment with 
 caspofungin® was instituted and control blood cultures 
as well as a urine culture were performed. The positive 
blood cultures were subcultivated in blood and chocolate 
agar and in different fungal media: sabouraud dextrose 
with antibiotics (SCG2 BioMerieux), BBL CHROMagar 
Candida Medium (Becton Dickinson) and potato dex-
trose agar plates, all incubated at 35 °C. On day + 6, eye 
fundus study, transthoracic echocardiogram and thora-
coabdominal radiology were all normal. On day + 8, a 
blood sample was tested for biomarkers 1–3 beta-d-glu-
can (BDG)  (Fungitell®, Assoc. Cape Cod Inc. USA) and 
CAGTA (Candida albicans IFA IgG,  Vircell® kit assay, 
Granada, Spain) with negative results. The isolation of 
yeasts only occurred in blood, chocolate and potato dex-
trose agar plates, while the other agar plates remained 
sterile after five days. R. mucilaginosa was identified phe-
notypically and by MALDI-TOF on day + 9, and antifun-
gal treatment was changed from Caspofungin (275  mg 
total doses) to  AmBisome®iv (130  mg/dl). On day + 10, 
due to a marked worsening of the abdominal pelvic com-
puted tomography (CT) with bilateral renal lithiasis, the 
double J was replaced and the immunosuppressors were 
suspended temporarily until resolution of the fungemia. 
After 16 days with  AmBisome®iv, the patient was asymp-
tomatic and blood and urine cultures for yeasts were all 
negative, as were serial biomarkers.
Case 2
An 80-year-old man with type 2 diabetes mellitus, nor-
motensive chronic hydrocephalus and a ventriculoperi-
toneal shunt performed on November 7, 2017, entered 
hospital 1 month later (62 days) due to fever of unknown 
origin and to confusional state. He was treated with 
empirical intravenous (iv) ceftazidime and iv vancomy-
cin. On day-28 the patient was discharged. Three months 
later, on February 8th (day 0) he returned to the hospital 
due to febrile peaks and neurological deterioration, pre-
senting an increase in acute phase reactants (C-reactive 
protein 23  mg/L, leukocytosis 13,010 cells/mm3 with 
neutrophilia 83.9%). Blood and urine samples for bac-
terial cultures were extracted. Yeasts were detected in 
two blood cultures on day + 5 (Versa TREKTM Auto-
mated Culture System, Thermo Scientific).  AmBisome® 
iv 375 mg was administered followed by doses of 200 mg 
per day. Oral 5-fluorocytosine was also administered at a 
concentration of 1750 mg/12 h. Blood was extracted for 
biomarkers study (BDG and CAGTA).
The positive blood cultures were subcultivated in blood 
and chocolate agar, and in the following fungal media: 
sabouraud dextrose with antibiotics (SCG2 BioMerieux), 
BBL CHROMagar Candida Medium (Becton Dickinson), 
and potato dextrose agar plates, all at 35 °C. On day + 6, 
as meningitis was suspected, a cranial CT scan revealed 
no new alterations, and a lumbar puncture was per-
formed. The cerebrospinal fluid (CSF) was suggestive of 
chronic subacute meningitis (proteins 73 mg/dl, glychor-
rhachia 48 mg/dl, 45 cells/mm3, 98% mononuclear) with 
negative conventional fungal and bacterial cultures. Due 
to clinical worsening, antifungal treatment was changed 
to iv anidulafungin. Yeast isolation only occurred in 
blood agar, chocolate agar and potato dextrose agar, while 
the other agar plates remained sterile after five days. The 
species R. mucilaginosa was phenotypically identified by 
MALDI-TOF on day + 7, and AmBisome was reinstated 
maintaining the anidulafungin for two more days. CSF 
study was positive for BDG (85.64 pg/ml) and for a pan-
fungal PCR that targets the ITS1 region of the rDNA [11]. 
Briefly, the assay was performed in a BioRad CFX96 unit 
(BioRad, Madrid, Spain). The assay was a Real Time PCR 
method that used the universal primers ITS1 and ITS2 
[12] and the kit Sensimix SYBR No-ROX (Bioline, Eco-
gen, Madrid, Spain). The PCR reaction (20 µL) contained 
0.8 µM each primer and 4.5 mM  MgCl2. The conditions 
for the PCR reaction were: 95  °C for 10  min; 45-cycle 
as follows: 10 s at 95 °C, 5 s at 54 °C, and 30 s at 72 °C. 
A melting program from 65 °C to 97 °C was performed. 
Melting curves were analyzed to discriminate unspecific 
amplifications from true amplicons. Agarose gel elec-
trophoresis was performed at 1.5% in order to verify the 
quality of the amplified product. Amplified fragments 
were sequenced and compared with the ITS nucleotide 
sequence database available in the Mycology Reference 
Laboratory (which contains more than 10,000 distinct 
sequences) and with the GenBank database (https:// 
www. ncbi. nlm. nih. gov/ genba nk/). The sequence matched 
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those of genus Rhodotorula and the species R. mucilagi-
nosa (90%). The moderate quality of the sequence did not 
permit us to achieve the species level but confirmed the 
genus Rhodotorula. The alignment with the sequences 
that best matched at GenBank is shown in the Additional 
file 1: Figure S1.
In spite of a total dosage of 1775 mg of AmBisome the 
patient died at day + 14.
Discussion and conclusions
Rhodotorula is a basidiomycetous yeast genus that 
belongs to the family Cryptococcaceae. These yeasts are 
universally distributed in nature (air, soil, water of lakes 
and oceans) and as saprophytes in skin, nails, and the res-
piratory, gastrointestinal and urinary tracts of humans. 
Their microbiological identification is based on the 
production of a carotenoid pigment, which gives them 
salmon-pink to coral-red appearance in initially smooth 
and moist colonies, which become rough and dull with 
time. Yeasts are ovoid to spherical (2–3 × 5–7 µm) occur-
ring singly or in chains, occasionally showing multilateral 
budding. Neither mycelium nor pseudomycelium is pro-
duced. They do not ferment carbohydrates and are urease 
positive. Rhodotorula mucilaginosa, Rhodotorula glutinis 
and Rhodotorula minuta are the most clinically relevant 
species of the genus [8].
Although generally these species are considered as 
being non-pathogenic, they can cause disease in both 
immunocompromised and immunocompetent patients, 
with R. mucilaginosa being responsible for more than 
70% of infections [13]. The first report of fungemia by 
Rhodotorula spp. appeared in 1960 [14]. Since then it 
has emerged as an opportunistic pathogen associated 
with indwelling CVCs and immunosuppresion (solid and 
hematological neoplasm patient) [6, 7]. Broad-spectrum 
antibiotics, corticosteroids, hyperalimentation, surgery, 
chronic renal failure, diabetes mellitus, granulocytopenia 
and damage to mucosa and skin have been suggested as 
predisposing factors for Rhodotorula infections [6].
In this article, two cases of proven fungemia by R. 
mucilaginosa diagnosed in a three months period in 
a 350 bed secondary hospital are described. Both cases 
corresponded to hospitalized patients with known risk 
factors, no previous history of azole treatment and are no 
time-related.
Sensitivity of conventional cultures in fungemia is 
around 50%. In patients with suspected fungal infec-
tion, guidelines recommend performing from two to four 
blood cultures and even incorporating specific bottles 
[15]. In this two cases, after the vision of yeasts in Gram, 
subcultures in blood and chocolate agar were performed 
as well as in the following fungal media: sabouraud dex-
trose agar with antibiotics (SCG2 BioMerieux), BBL 
CHROMagar Candida Medium (Becton Dickinson) and 
potato dextrose agar medium. In both cases, the isolation 
of yeast only occurred in blood, chocolate and potato 
dextrose agar, while the other agar plates remained sterile 
(Fig. 1), which leads us to recommend the use of various 
culture media to increase sensitivity of fungal isolation. 
Both strains were identified by using MALDI-TOF MS 
(Bruker Daltonics, Billerica, MA, USA) and API32C aux-
onogram (profile 546175011) [5] (BioMerieux, France). 
The lack of growth of Rhodotorula isolates in two com-
mon, commercially available, fungal media (sabouraud 
dextrose agar with antibiotics (SCG2 (BioMerieux) and 
BBL CHROMagar Candida Medium (Becton Dickin-
son) is not due either to the strain or to the media as in 
the other subcultures the strains were able to grow. The 
source of lack of grow could be found in the two step 
process involving blood culture in bottle and subsequent 
subculture on these specific agar plate media. In fact, 
these media are routinely used for the isolation of Rho-
torula spp. in other superficial and deep samples. Spe-
cifically, in the last five years this yeast has been isolated 
in 19 samples (skin biopsies, ascitic and peritoneal liq-
uids, blood, otics and ungueal samples) using these same 
media. The characteristics of the strains, the low fungal 
burden or the blood culture media could be in the origin 
of the lack of grow.
The Versa TREKTM Automated Culture System has 
been successfully used for Candida spp. however specific 
studies with Rhodotorula spp. have not being performed. 
Deeper studies should be done to confirm this findings.
As expected, MIC values (µg/mL;  Sensititre® Yeast One 
panel-Trek Diagnostic Systems, Cleveland, OH, USA) 
were high for echinocandins (> 8) and fluconazole (> 256); 
variable for all other azoles tested: voriconazole (4 and 
8), posaconazole (2), itraconazole (1 and 2); and low for 
amphotericin B (2 and 0.25) and 5-fluorocytosine (0.125 
and < 0.006), respectively. The molecular mechanism 
behind the reduced susceptibility to echinocandins among 
basidiomycetous yeasts remains poorly understood [4, 5, 
Fig. 1 Subcultures of blood culture: a Rhodotorula mucilaginosa on 
Sabouraud agar; b and on potato dextrose agar
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9, 10]. Carotenoid pigments produced by R mucilaginosa 
strains could play a role in imparting resistance against 
echinocandins but has not being proven.
As other authors [9] and guidelines [16] reported pre-
viously: (i) amphotericin B should be the treatment of 
choice in cases of R. mucilaginosa infection, (ii) 5-fluo-
rocytosine could be considered as an adjuvant treatment 
given its good in vitro performance and (iii) withdrawl of 
CVC if present is essential [16] given the ability of this 
yeast to adhere to catheters or other prosthetic devices by 
producing biofilms [5]. The length of treatment of Rhodo-
torula fungemia is variable in the literature, ranging from 
14 to 41 days [13].
Although R. mucilaginosa contains BDG in its wall 
[17], only five cases have been reported in which this 
biomarker was used for diagnosis [18]. Serum levels of 
BDG in both cases described here were low (4.4  pg/ml 
and 67  pg/ml, respectively) as also previously reported 
by other authors [18, 19]. However, the detection of BDG 
in cerebrospinal fluid in the second patient was very use-
ful to support the etiology of meningitis. The reason why 
obtaining low serum levels of BDG in these species is 
unknown but it might be because the capsule prevents 
releasing this polysaccharide to serum, or because of lim-
ited or transient fungemia.
Panfungal PCR, based on the amplification of the ITS1 
region of ribosomal DNA, was performed only in case 2, 
obtaining a positive result and highlighting the usefulness 
of this type of technique as complementary to conven-
tional diagnostic techniques. However, the quality of the 
sequence did not allow for identification at the species 
level, probably because the CSF is not the most suitable 
sample for a panfungal assay.
An early and adequate treatment with the antifungal of 
choice as well as the elimination of predisposing factors 
(replacement of the double J and temporary suspension 
of the immunosuppressors) led to a clarification of yeasts 
in blood and to a clinical cure without sequels of the first 
patient. Unfortunately, this was not enough in the second 
case, mainly due to a more precarious basal situation and 
the fact that the infection was disseminated with menin-
gitis (positive results of panfungal PCR and CSF BDG).
In conclusion, a rapid identification of fungi caus-
ing fungemia is a key issue for an adequate therapy. 
When yeasts grow in blood cultures, we must consider 
that genera other than Candida spp such as Malasse-
zia, Trichosporon, Cryptococcus and Rhodotorula may 
be involved in the infection. Patient risk factors should 
guide us to incorporate alternative culture media such 
as Dixon agar for Malassezia (patients with parenteral 
lipid nutrition), media supplemented with catecho-
lamines or coffee for Cryptococcus (in HIV-patient), 
or potato dextrose agar for Rhodotorula (in vascular 
catheterization and leukaemia) or Trichosporon (in leu-
kaemia patients and prophylaxis with oral polyenes in 
ICU). The isolation and recognition of rare yeasts in 
invasive infections, as well as the detection of intrinsic 
antifungal resistance, imply a working overload in the 
mycology laboratory. Timely identification and rapid 
antifungal therapy is essential to reducing the morbid-
ity and mortality of the patient.
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